These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29521134)

  • 1. Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects.
    Zhou S; Tao M; Wang Y; Wang L; Xie L; Chen J; Zhao Y; Liu Y; Zhang H; Ou N; Wang G; Shao F; Aa J
    Xenobiotica; 2019 Mar; 49(3):375-380. PubMed ID: 29521134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP3A4*1G, CYP3A5*3, POR*28, and ABCB1 C3435T on the pharmacokinetics of nifedipine in healthy Chinese volunteers.
    Wang XF; Yan L; Cao HM; Wei LM; Yang WH; Zhang SJ; Zhang LR
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):737-45. PubMed ID: 26104034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients.
    Zhou LY; Zuo XC; Chen K; Wang JL; Chen QJ; Zhou YN; Yuan H; Ma Y; Zhu LJ; Peng YX; Ming YZ
    J Clin Pharm Ther; 2016 Jun; 41(3):341-7. PubMed ID: 27149910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers.
    Zhang J; Dai Y; Liu Z; Zhang M; Li C; Chen D; Song H
    Ther Drug Monit; 2017 Aug; 39(4):406-411. PubMed ID: 28700521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
    Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
    J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A4∗18B and CYP3A5∗3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects.
    Tao XR; Xia XY; Zhang J; Tong LY; Zhang W; Zhou X; Liu ZH; Song HT
    Eur J Pharm Sci; 2015 Aug; 76():238-44. PubMed ID: 25976223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
    Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation
.
    Huang Y; Wen G; Lu Y; Wen J; Ji Y; Xing X; Li Y; Wen J; Yuan H
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):109-118. PubMed ID: 27841150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
    Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
    Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects.
    Zhou S; Wang Y; Wang L; Xie L; Chen J; Liu Y; Zhang H; Zhao Y; Ou N; Shao F
    Clin Drug Investig; 2019 Jan; 39(1):85-96. PubMed ID: 30368658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery.
    Zhang W; Yuan JJ; Kan QC; Zhang LR; Chang YZ; Wang ZY; Li ZS
    Eur J Anaesthesiol; 2011 Apr; 28(4):245-50. PubMed ID: 21513075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers.
    Xiang Q; Li C; Zhao X; Cui YM
    J Clin Pharm Ther; 2017 Jun; 42(3):345-349. PubMed ID: 28244604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influences of ABC transporter and CYP3A4/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects.
    Li J; Wang X; Ning C; Wang Z; Wang Y; Zheng M; Zhang S; Lu Y; Zhang Y; Li N; Chen X; Zhao D
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1125-1133. PubMed ID: 32382947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition.
    Yin OQ; Tomlinson B; Chow MS
    J Clin Pharmacol; 2010 Oct; 50(10):1136-41. PubMed ID: 20133509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease.
    He BX; Shi L; Qiu J; Zeng XH; Zhao SJ
    J Clin Pharmacol; 2014 Apr; 54(4):462-7. PubMed ID: 24214373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of
    Liu S; Shi X; Tian X; Zhang X; Sun Z; Miao L
    Front Pharmacol; 2017; 8():176. PubMed ID: 28408884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.
    Lee HI; Byeon JY; Kim YH; Lee CM; Choi CI; Jang CG; Bae JW; Lee YJ; Lee SY
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1417-1426. PubMed ID: 30039199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.